Business
Neurogene Reports First Quarter 2026 Financial Results and Highlights Recent Updates
NEW YORK, May 12, 2026--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced first quarter 2026 financial results and highlighted recent corporate updates.
About this update from Neurogene Inc.
[{"type":"text","content":"Dosed ~90% of participants in Embolden™ registrational trial of NGN-401 for Rett syndrome; on track to complete dosing in the second quarter of 2026","length":148,"tagName":"p","attribs":{}},{"type":"text","content":"NGN-401 has been generally well-tolerated, with no cases of HLH at the 1E15 vg dose; additional interim Phase 1/2 data expected mid-2026","length":136,"tagName":"p","attribs":{}},{"type":"text","content":"Presentation at ASGCT Meeting highlighted therapeutic rationale for ICV delivery in CNS-targeted gene therapy, including NGN-401","length":128,"tagName":"p","attribs":{}},{"type":"text","content":"Strong cash position provides runway through first quarter of 2028","length":66,"tagName":"p","attribs":{}},{"type":"text","content":"NEW YORK, May 12, 2026--(BUSINESS WIRE)--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced first quarter 2026 financial results and highlighted recent corporate updates.","length":305,"tagName":"p"},{"type":"text","content":""The significant unmet need in Rett syndrome and strong interest among physicians and caregivers continue to drive momentum for NGN-401, with approximately 90% of participants dosed in the Embolden™ registrational trial," stated Rachel McMinn, Ph.D., Founder and Chief Executive Officer of Neurogene. "We continue to be encouraged that NGN-401 at the 1E15 vg dose has been generally well-tolerated. We are laser-focused on completing dosing in Embolden in the coming weeks and look forward to providing an update on this important clinical development milestone. In parallel, we are continuing to strengthen the organization and execute on early commercial-readiness activities to support a successful potential launch of NGN-401."","length":751,"tagName":"p"},{"type":"text","content":"First Quarter 2026 and Recent Highlights","length":40,"tagName":"p"},{"type":"text","content":"NGN-401 Gene Therapy for the Treatment of Rett Syndrome","length":55,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Announced today that ~90% of participants have been dosed in the Embolden registrational trial, and the Company is on track to complete dosing in the second quarter of 2026","length":172,"tagName":"p","attribs":{...